Unicycive Therapeutics Secures Patent for Innovative Kidney Treatment

Unicycive Therapeutics Advances Kidney Disease Treatment with New Patent

Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company based in California, proudly announces the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for its innovative drug UNI-494, aimed at treating Chronic Kidney Disease (CKD). This patent strengthens its intellectual property portfolio, following a prior method of use patent concerning the treatment of Acute Kidney Injury (AKI) with UNI-494.

Significance of the New Patent

“As we strive for FDA approval of our primary product, oxylanthanum carbonate, the announcement of the patent for UNI-494 is a promising development for our second investigational drug,” expressed Shalabh Gupta, MD, CEO of Unicycive Therapeutics. This intellectual property coverage signifies additional opportunities for partnerships that could accelerate further research and development initiatives.

Progress and Innovations

Unicycive has successfully completed a Phase I clinical study involving healthy volunteers for UNI-494. The drug has also achieved Orphan Drug Designation from the FDA, specifically for preventing Delayed Graft Function (DGF) in kidney transplant patients, showcasing its potential as a groundbreaking treatment option.

Understanding UNI-494 and Its Mechanism

UNI-494 is a novel nicotinamide ester derivative functioning as a selective ATP-sensitive mitochondrial potassium channel activator. This innovative mechanism may be pivotal in restoring mitochondrial function—crucial for patients experiencing acute kidney injury and chronic kidney disease. Patent protections extend across the U.S., Europe, and various global applications, accentuating the drug's significance in the medical realm.

The Challenge of Acute Kidney Injury

Acute kidney injury (AKI) remains a significant concern, defined by a sudden decline in kidney performance, which has implications for survival and long-term health. The causes of AKI range from sepsis and ischemia to drug-induced effects, creating urgent healthcare needs. Notably, DGF represents a particular type of AKI that emerges shortly after a kidney transplant, affecting half of transplant patients. With such a high incidence, addressing these complications is critical.

About Unicycive Therapeutics

Unicycive Therapeutics focuses on developing revolutionary treatments targeting kidney diseases. The company’s lead investigational option, oxylanthanum carbonate, addresses hyperphosphatemia in CKD patients on dialysis. Meanwhile, UNI-494 seeks to combat conditions related to acute kidney injuries and has also shown promise in its Phase 1 safety studies.

For more detailed insights about our research and breakthrough products, feel free to visit our website for updates, as we also maintain an active presence on various professional networks.

Frequently Asked Questions

What is UNI-494 and how does it work?

UNI-494 is a novel drug designed to activate mitochondrial potassium channels, potentially restoring mitochondrial function and aiding in the treatment of various kidney diseases.

What recent patent has Unicycive Therapeutics received?

The company has announced the U.S. Patent 12,377,082 for UNI-494, specifically aimed at treating Chronic Kidney Disease.

What is the purpose of Orphan Drug Designation?

Orphan Drug Designation is granted to drugs that treat rare conditions, allowing for incentives such as market exclusivity, tax credits, and assistance in the development process.

What does the Phase I clinical study entail?

The Phase I clinical study is a safety trial involving healthy volunteers to assess the drug's safety profile before further efficacy studies.

How are acute kidney injuries relevant to UNI-494?

UNI-494 aims to treat conditions resulting from acute kidney injuries, which are critical health issues for many patients, especially following kidney transplants.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.